Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?

ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer.

Study sheds light on the composition of nuclear matrix in Arabidopsis thaliana

Chromatin is a unique DNA and protein complex that makes up the chromosomes. Specific proteins (histones) wind up the DNA like small cable drums to

February 24, 2024

Penn research uncovers key biomarker for diagnosing sarcoidosis

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the US, more often people who are Black and more women than

September 3, 2024

AbbVie’s migraine medication Qulipta gets positive CHMP opinion – Pharmaceutical Technology

AbbVie’s Qulipta could bring relief to over 40 million migraine sufferers in Europe. Source: Shutterstock / Tunatura. AbbVie announced the European Medicines Agency’s (EMA) Committee

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.